Enanta Pharmaceuticals In... (ENTA)
5.58
-0.13 (-2.28%)
At close: Mar 31, 2025, 3:37 PM
Enanta Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
| Revenue | 67.64M | 79.2M | 86.16M | 97.07M | 122.47M | 205.2M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Cost of Revenue | n/a | n/a | 2.97M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | 67.64M | 79.2M | 83.19M | 97.07M | 122.47M | 205.2M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Operating Income | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M | 36.74M | 88.33M | 24.61M | 30.84M | 124.15M | 18.98M | 9.03M | 21.29M | 25.3M | 6.94M |
| Interest Income | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M | 8.82M | n/a | 2.53M | 1.74M | 968K | 467K | 248K | 118K | 83K | 14K |
| Pretax Income | -117.79M | -131M | -122.19M | -107.58M | -35.02M | 45.56M | 93.12M | 26.95M | 32.56M | 125.45M | 19.27M | 9.63M | 21.4M | 23.31M | 7.75M |
| Net Income | -116.05M | -133.82M | -121.75M | -79M | -36.17M | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M | 9.63M | 21.4M | 23.31M | 7.9M |
| Selling & General & Admin | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.3M | 5.04M | 6.11M |
| Research & Development | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M | 142.21M | 94.86M | 57.45M | 40.46M | 23.19M | 18.74M | 16.84M | 15.12M | 11.55M | 9.72M |
| Other Expenses | n/a | n/a | 83K | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283K | 598K | n/a | 5.04M | 309K |
| Operating Expenses | 189.33M | 216.41M | 210M | 206.65M | 164.11M | 168.46M | 118.3M | 78.2M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Interest Expense | 10.94M | 5.15M | 1.57M | n/a | n/a | 8.82M | 4.85M | 40K | 45K | 8K | 18K | 31K | n/a | 3.16M | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 189.33M | 216.41M | 210M | 206.65M | 164.11M | 168.46M | 118.3M | 78.2M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Income Tax | -1.74M | 2.82M | -433K | -28.58M | 1.15M | -826K | 21.16M | 9.24M | 10.89M | 46.46M | -15.17M | -221K | n/a | 3.16M | -157K |
| Shares Outstanding (Basic) | 21.16M | 20.97M | 20.6M | 20.17M | 19.94M | 19.58M | 20.65M | 19.07M | 18.93M | 18.67M | 18.36M | 9.79M | 1.16M | 1.16M | 12.75M |
| Shares Outstanding (Diluted) | 21.16M | 20.97M | 20.6M | 20.17M | 19.94M | 20.97M | 20.65M | 19.41M | 19.22M | 19.3M | 19.18M | 9.79M | 2.64M | 2.64M | 14.13M |
| EPS (Basic) | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.02 |
| EPS (Diluted) | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 0.52 | 0.59 | 0.02 |
| EBITDA | -104.51M | -123.48M | -119.22M | -104.25M | -37.99M | 40M | 90.85M | 26.75M | 32.5M | 124.79M | 19.34M | 9.25M | 21.57M | 26.97M | 8.3M |
| Depreciation & Amortization | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M | 3.26M | 2.52M | 2.14M | 1.66M | 639K | 352K | 221K | 172K | 499K | 553K |